What happened?
Shares of vaccine biotechnology company Novavax (NASDAQ: NVAX) jumped 8.8% in the afternoon session after the company reported third-quarter 2026 financial results and raised its full-year adjusted total revenue outlook.
Total revenue for the quarter was $68 million. Novavax raised its full-year 2026 adjusted total revenue outlook by $145 million to a $400 million mid-point. In addition, the company received a $125 million milestone after Sanofi initiated a Phase 3 combination vaccine trial in Europe. Novavax recorded a third-quarter 2026 net loss of $31 million compared to a net loss of $202 million for the same timeframe in 2025.
Is now the time to buy Novavax? Access our full analysis report here, it’s free.
What is the market telling us
Novavax’s shares are extremely volatile and have had 50 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 2 days ago when the stock gained 7.2% on the news that election results confirmed that Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty around drug pricing policy. As reported by CNBC, Wall Street analysts project that the biopharmaceutical sector's recovery will strengthen in the wake of the congressional election outcome. Investors had feared potential disruptions to healthcare policies, but analysts noted that drug pricing legislation is unlikely to dominate the new legislative agenda. Prior statutory frameworks already established expanding annual Medicare price negotiations, meaning existing government policies will remain intact without unexpected new restrictions.
Furthermore, broader equity markets and index futures rebounded as investors interpreted the shifting balance of power in Washington as a stabilizing dynamic. The presence of congressional checks and balances is widely viewed by market strategists as a moderating force on executive policy decisions, creating a predictable regulatory climate that supports ongoing investments across pharmaceutical and biotechnology developers.
Novavax is up 49.4% since the beginning of the year, but at $10.65 per share, it is still trading 16.9% below its 52-week high of $12.82 from October 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Novavax’s shares 5 years ago would now be looking at only $61.57.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
